Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Drug Safety Evaluation Could Start With Short Cardiac Function Studies

Executive Summary

Members of FDA's Drug Safety & Risk Management Advisory Committee are proposing short-term studies of cardiac function as a feasible method to evaluate cardiovascular risks associated with attention deficit/hyperactivity disorder drugs

You may also be interested in...



Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says

Warnings about cardiovascular risk associated with pediatric use of attention deficit/hyperactivity disorder treatments should be extended to Lilly's Strattera, FDA's Pediatric Advisory Committee recommended

Related Content

UsernamePublicRestriction

Register

PS046874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel